Autolus Therapeutics (AUTL) Stock Price, News & Analysis

Company Overview

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma. Additional clinical and preclinical programs address targets such as BCMA in multiple myeloma and solid tumor antigens, as well as novel constructs aimed at improving T cell persistence and tumor microenvironment penetration. Autolus collaborates with academic institutions and research partners to advance its pipeline and validate emerging technologies.

Founded in 2014 as a spin-out from University College London, Autolus is headquartered in London, U.K., with operational sites in the United States and Europe to support clinical trials and manufacturing scale-up. The company is led by Chief Executive Officer Christian Itin, whose background in cell therapy and immuno-oncology guides a leadership team of experienced industry executives and scientific experts. Autolus is committed to expanding global access to its therapies through regulatory filings and strategic partnerships in key markets.

Key Stats

• Today's Range: $2.26 to $2.33
• 50-Day Range: $1.40 to $2.54
• 52-Week Range: $1.17 to $2.58
• Volume: 1.91 million shs
• Average Volume: 2.84 million shs
• Market Capitalization: $609.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Autolus Therapeutics Stock Analysis - MarketRank™

Autolus Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 277th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Autolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Autolus Therapeutics has a consensus price target of $10.00, representing about 336.7% upside from its current price of $2.29.

Amount of Analyst Coverage

Autolus Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.75) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Autolus Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Autolus Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Autolus Therapeutics has a P/B Ratio of 8.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.30% of the float of Autolus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Autolus Therapeutics has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Autolus Therapeutics has recently decreased by 23.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Autolus Therapeutics does not currently pay a dividend.

Dividend Growth

Autolus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Autolus Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 8 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.

MarketBeat Follows

6 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Autolus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,708.00 in company stock.

Percentage Held by Insiders

25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/04/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AUTL
• CIK: 1730463
• Web: www.autolus.com
• Phone: 442038296230
• Fax: N/A
• Employees: 330
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Autolus Therapeutics: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +336.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$287.53 million
• Net Margins: -238.66%
• Pretax Margin: -238.08%
• Return on Equity: -178.66%
• Return on Assets: -49.34%

Debt

• Debt-to-Equity Ratio: 1.04
• Current Ratio: 4.89
• Quick Ratio: 4.40

Sales & Book Value

• Annual Sales: $75.39 million
• Price / Sales: 8.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 8.18

Miscellaneous

• Outstanding Shares: 266,160,000
• Free Float: 197,759,000
• Market Cap: $609.51 million
• Optionable: Optionable
• Beta: 2.10